+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Variability in response to D-penicillamine: pharmacokinetic insights



Variability in response to D-penicillamine: pharmacokinetic insights



Agents and Actions. Supplements 44: 203-207



D-Penicillamine (D-Pen) is one of a group of chemically similar drugs which are efficacious in rheumatoid arthritis and which have similar patterns of biotransformation and similar toxicity. These similarities suggest associations between the transformations of D-Pen and it's toxicity and efficacy. Oxidation, methylation, formation of stable adducts with protein, interaction with metals and reduction of oxygen species have been shown in-vivo or in-vitro. Metabolism to a sulphoxide may occur and may be relevant to toxicity. Intracellular concentrations of D-Pen and metabolites are largely unknown.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034181610

Download citation: RISBibTeXText

PMID: 8372729


Related references

Pharmacokinetic and metabolism of D- and L-penicillamine. 2. Distribution of D- and L-penicillamine-14C in the rat organism after oral administration. Arzneimittel-Forschung 24(7): 1043-1046, 1974

Hypothermic response in both restrained and unrestrained rats to the selective delta opioid agonist 2 d penicillamine 5 l penicillamine enkephalin. Federation Proceedings 44(4): 1345, 1985

Pharmacokinetic factors influencing variability in human drug response. Scandinavian Journal of Rheumatology. Supplement 39: 5-14, 1981

Doxorubicin in lymphoma: association between pharmacokinetic variability and clinical response. Therapeutic Drug Monitoring 32(1): 50-52, 2010

Pharmacokinetic factors as causes of variability in response to non-steroidal anti-inflammatory drugs. Agents and Actions. Supplements 17: 59-63, 1985

Pharmacokinetic and pharmacodynamic factors causing variability in response to neuroleptic drugs. Psychopharmacology Series 3: 266-274, 1987

Intensity of systemic exposure and interpatient pharmacokinetic variability as determinants of response to chemotherapy. Clinical Pharmacology & Therapeutics 41(2): 247, 1987

Emerging Insights for Translational Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Studies: Towards Prediction of Nose-to-Brain Transport in Humans. Aaps Journal 17(3): 493-505, 2015

Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Canadian Journal of Cardiology 29(7 Suppl): S24-S33, 2013

Combination therapy with andrographolide and d-penicillamine enhanced therapeutic advantage over monotherapy with d-penicillamine in attenuating fibrogenic response and cell death in the periportal zone of liver in rats during copper toxicosis. Toxicology and Applied Pharmacology 250(1): 54-68, 2010

Pharmacokinetic studies on 14 C-labelled penicillamine. Arzneimittel-Forschung 22(9): 1426-1433, 1972

Pharmacokinetic interactions of penicillamine in rheumatoid arthritis. Journal of Rheumatology 16(4): 473-474, 1989

Pharmacokinetic studies following administration of 14 C-D-penicillamine to rats. Arzneimittel-Forschung 27(6): 1152-1158, 1977

Cells from mice exposed chronically to D-penicillamine show proliferative responses to D-penicillamine-treated self (macrophage/dendritic cells): a graft-versus-host response?. Annals of the New York Academy of Sciences 681: 319-322, 1993

Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform. Toxicology. 111(1-3): 289-303, 1996